We sought to describe the relationship between the elimination of out-of-pocket costs and women's use of preventive care office visits and long-acting reversible contraception after accounting for baseline levels of cost sharing. OBJECTIVES: The objective of this analysis was to describe the relationship between the elimination of out-of-pocket costs and utilization of preventive care visits and long-acting reversible contraception insertion while taking baseline cost sharing levels under consideration. STUDY DESIGN: In 2017, we used administrative health plan data to examine changes in out-of-pocket costs and service utilization among 2,172,065 women enrolled in 15,118 employer-based health plans between 2008 and 2015. We used generalized estimating equations to examine utilization patterns. RESULTS: Women in this sample generally had low costs at baseline ($24 and $29 for preventive care visits and long-acting reversible contraception insertion, respectively). The elimination of baseline out-ofpocket costs were related to changes in the utilization of both services but more consistently for contraceptive device placement. Women whose low/moderate out-of-pocket costs were eliminated were more likely to use
I
n 2017, the Trump administration rolled back restrictions on patient cost sharing for contraception-related services established by the Affordable Care Act (ACA) in 2012. In contrast to language included in the administration's ruling and based on evidence generated by decades of clinical and epidemiological studies, 1 there is widespread acceptance that contraception use effectively prevents pregnancy and is a high-value service for reproductive-aged women. As policymakers continue to consider revising aspects of the ACA, including other limits on patient cost sharing, it is crucial to understand the performance of innovative aspects of this policy.
Individuals may disagree about how to reform our health care system, but there is considerably more consensus that too much health care spending is on services that do not advance health. Value-based insurance design (V-BID), a strategy to encourage health care consumers to use high-value medical services, has bipartisan support. Under V-BID principles, consumers' out-ofpocket costs (OOPCs) are reduced or eliminated for services with strong evidence supporting their ability to improve clinical outcomes and/or increase health system efficiency. 2 V-BID was incorporated into Section 2713 of the ACA and requires nonegrandfathered health insurance plans to cover a range of services, including contraception, without patient OOPCs. 3 Removing OOPCs has the potential to increase women's use of recommended services, including preventive care and contraception services. There is particularly strong evidence that the utilization of the most effective methods of contraception-long-acting reversible contraception (LARC)-is inversely associated with OOPCs. [4] [5] [6] [7] Increasing the use of LARC for women, which includes intrauterine devices and implants, is a key strategy in the efforts to decrease the United States' high unintended pregnancy rate. 8 Studies demonstrate that women's OOPCs for some preventive services, including contraception, declined substantially following the ACA, 9-14 but it is not clear whether these declines have led to increased utilization. 11, 12, 15 Perhaps these studies were conducted too early to observe the full impact of cost-sharing elimination on utilization. Alternatively, studies to date have not accounted for variation in baseline OOPCs and were conducted among women with rather low baseline out-of-pocket costs. 12, 14 It is not clear that eliminating a small (eg, $20) payment will result in meaningful changes in utilization for most women. Furthermore, it is possible that women are more price sensitive for some health services than others.
Answers to these questions are key to informing value-based insurance designs. Furthermore, this information would help distinguish between 2 possible reasons that studies to date have not consistently observed increased utilization of some services following the ACA including the following: (1) that elimination of cost sharing is not an effective approach and (2) that OOPCs were already low. Accordingly, our objective was to describe the relationship between the elimination of OOPCs and utilization of preventive services while taking baseline cost sharing levels under consideration. Our analysis examines the relationship between cost sharing and utilization for 2 services relevant to reproductive-aged women that the ACA requires to be covered without OOPCs: preventive care office visits (POV) and insertion of LARC devices. 16, 17 We expected that health plans would fall mainly into the following 4 categories: (1) plans with high OOPCs that fell to zero; (2) plans with low OOPCs that fell to zero; (3) plans that always had OOPCs; and (4) plans that never had OOPCs. We hypothesized that women enrolled in plans with high OOPCs at baseline would increase the use of services to a greater degree than women with low or no OOPCs at baseline, following cost-sharing elimination.
Materials and Methods
We used deidentified data from the Clinformatics Data Mart Database (OptumInsight, Eden Prairie, MN) to examine the relationship between changes in OOPCs and service utilization among commercially insured women between 2008 and 2015. Our data source includes patient copayment, deductible, and coinsurance amounts along with standardized costs and demographic characteristics such as patient age, race, and whether a patient had an income below 400% of the 2015 federal poverty level. This study was deemed exempt by our institutional review board.
Our analytic sample was drawn from a population of 6,047,781 females aged 15e45 years who were enrolled in an employer-based health plan. We restricted our sample to women with continuous enrollment in a single employer-based health plan for at least 1 year between 2008 and 2015. Women with evidence of having undergone a hysterectomy were included in our analysis until the month prior to their surgery date. To estimate the level of OOPCs for a specific service, a woman's health plan needed to be utilized for our target services during 2008e2009 (preperiod) and 2014e2015 (postperiod); therefore, health plans (and their members) that were not utilized at least once in both time periods were excluded from the analysis for that service.
We identified service utilization-our outcome of interest-and service date for a given patient using International Classification of Diseases diagnosis or procedure codes (revisions 9 and 10) and/or current procedural terminology (CPT4/HCPCS) procedure codes. Total OOPC was calculated by summing patient copayments, coinsurance, and deductible payments for each service. All payments and cost estimates were adjusted to 2015 dollars using the Medical Consumer Price Index. Service utilization was calculated as the proportion of women in the analytic sample with at least 1 claim for that service for each year.
We had the following 2 key predictors of interest related to patient OOPCs: (1) the elimination of OOPCs and (2) the level of baseline OOPCs. To construct these measures to include in our patientspecific model, we conducted a planspecific analysis to calculate the mean and median OOPCs for each service for each plan in each year. Based on observed levels of OOPCs over time, plans were defined as treatment plans if the following were present: (1) they had non-zero median OOPCs at baseline, and (2) OOPCs declined to zero by the end of 2015.
Treatment plans were further divided into high-and low/moderate-cost plans based on median baseline OOPCs for the service of interest. This process was repeated for each service outcome and resulted in 4 groups of plans specific to each service: (1) (3) plans that always had OOPCs (always-OOPC plans); and (4) plans that never had OOPCs (never-OOPC plans).
For POV, we defined high-cost treatment plans as those with median OOPCs for preventive care visits at or greater than $100. For LARC insertion, we AJOG at a Glance Why was this study conducted? This study clarifies whether cost sharing level is a barrier to use of 2 recommended preventive care services: preventive care office visits and insertion of long-acting reversible contraception. In contrast to previous studies, we considered levels of baseline cost sharing because we expected that women may be more responsive to the elimination of higher baseline levels of out-of-pocket cost than lower baseline levels.
Key Findings
Service use increased after costs were eliminated, especially for contraception device insertion among women with the highest levels of baseline costs.
What does this add to what is known?
Findings suggest that even among commercially insured women, there was costrelated unmet demand for these services, and the elimination of cost sharing appears to reduce this barrier.
Original Research GYNECOLOGY ajog.org 93.e2 American Journal of Obstetrics & Gynecology JULY 2018 defined high-cost treatment plans as those with median OOPCs at or greater than $200. These definitions were based on observed variation in OOPCs levels and a literature review. 4 We used generalized estimating equations to compare service utilization across our plan categories while accounting for dependence because of repeated measures within a person. We created patientspecific models for each outcome-POV and LARC insertion. A third model for LARC insertion was performed on a subsample of contraceptive users (ie, individuals with any contraception-related claims [office visit, procedure, or medication fill] in any observed year).
Models included linear and quadratic time trends to account for underlying trends in utilization over time. Women appear in the model in 1 of 6 categories based on their plan group and whether the plan state is before or after the elimination of OOPCs including the following: (1) high-cost treatment plans during the period of high OOPCs (highcost treatment plan, preperiod); (2) high-cost treatment plans during the period of zero OOPCs (high-cost treatment plan, postperiod); (3) low/ moderate-cost treatment plans during period of low/moderate OOPC costs (low/moderate-cost treatment plans, preperiod); (4) low/moderate-cost treatment plans during the period of zero OOPCs (low/moderate-cost treatment plans, postperiod); (5) always-OOPC plans; and (6) never-OOPC plans. In all models, the reference group was low/moderate-treatment plans during a period of low/moderate OOPCs because this was the most common category of health plans prior to the policy change.
All models included covariates for age, race, poverty status, region, and insurance product. Poverty status was calculated using total household income and household size. Patient utilization was modeled with a binomial distribution and logit link function. An exchangeable 
Results
There were 2,172,065 females aged 15e45 years enrolled in 15,118 employer-based health plans between 2008 and 2015. There were 13,443 and 1493 health plans that were utilized in both the pre-and postperiods for POV and LARC insertion, respectively. After limiting to utilized plans, there were 1,678,148 and 1,148,562 unique women in our POV and LARC insertion analytic samples. Supplemental Figure 1 shows how we constructed the analytic sample.
Reflecting the fact that our sample was drawn from employer-based health plans, women were predominantly white, and greater than half resided in households above 400% of the federal poverty level (FPL). (See Supplemental Table for participant characteristics.) Table 1 shows the distribution of this sample of health plans across our defined plan categories over time. During 2008 and 2009, most plans had low/moderate levels of OOPCs for POV and LARC insertion, but a higher proportion of plans had higher OOPCs for LARC insertion (13.9%) than for POVs (2.4%).
The elimination of OOPCs occurred quickly after the implementation dates of mandated coverage of preventive services (September 2010) and contraceptive services (August 2012; Figure 1 ). By 2015, the proportion of women without OOPCs for POV and LARC insertion reached 97.1% and 93.9%, respectively. Even before OOPCs were eliminated, OOPC levels were modest for both services ($24 and $29 for POV and LARC insertion, respectively).
Generalized estimating equation model results for POV and LARC insertion are shown in Table 2 . Race, poverty status, geographic region, plan type, and age were all associated with the utilization of POV and LARC insertion. In the adjusted models, women at or below 400% of the FPL had decreased odds of POV and increased odds of LARC placement, as compared with higher-income women (odds ratio [OR], 0.67; confidence interval [CI], 0.67e0.67 and OR, 1.13; CI, 1.11e1.15, respectively).
After adjusting for covariates, health plan group-our predictor of interestwas consistently associated with the utilization of both POV and LARC initiation. As compared with women in low/ moderate-cost treatment plans in the preperiod, women in low/moderatetreatment plans in the postperiod and those in plans that never had OOPCs had slightly increased odds of utilization of POV (OR, 1.05; CI, 1.04e1.05, and OR, 1.03; CI, 1.03e1.04, respectively). The elimination of OOPCs had a more consistent relationship with LARC insertion than with POV utilization. LARC insertion was inversely associated ajog.org
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with OOPCs. In the preperiod, women in high-cost treatment plans were less likely than women in low/moderate-cost treatment plans to have LARC insertion (OR, 0.92; CI, 0.86e0.97), but their odds of utilization were significantly higher after OOPCs were eliminated (postperiod) (OR, 1.15; CI, 1.09e1.20). As compared with the women in low/ moderate-cost treatment plans during the preperiod, the odds of having a LARC device placed was higher among all groups of women when there were no OOPCs (postperiod). Predicted probabilities of POV utilization and LARC insertion by plan groups are shown in Figure 2 . Utilization of POV was highest among women in health plans that never had OOPCs (44.1%) and in those that eliminated low/moderate costs (low/moderatetreatment plans, postperiod) (44.5%). Utilization was lowest among women in high-cost treatment plans during the preperiod (36.6%). For LARC placement, the probability of utilization was highest among women enrolled in highcost treatment plans during the postperiod (2.1%).
A similar pattern of LARC insertion was observed when limiting our sample to contraceptive users. Pairwise comparisons concluded that after the elimination of OOPCs, women with high OOPCs at baseline had statistically higher utilization rates than any other group (Supplemental Figures 2 and 3) .
Comment
In this sample of women with employerbased insurance, the utilization of POV and LARC insertion generally increased following the elimination of OOPCs, but changes in utilization depended on baseline costs prior to the ACA. Eliminating high OOPCs appeared to be particularly important for LARC: the largest effect observed was among women experiencing the largest decline in OOPCs for this service, in which we saw a 0.8% increase in LARC insertion rates during the first 1e2 years of exposure to no-cost LARC devices.
It should also be recognized that a large majority of the women in this population of health plans already had Values in parentheses are 95% confidence intervals. A, Pairwise differences between all groups are significant at the level of P < .05. B, Pairwise differences between all groups are significant at the level of P < .05 except for Always had cost vs High cost preperiod and Never had cost vs Low/ moderate cost postperiod. C, Pairwise differences between all groups are significant at the level of P < .05 except for High cost preperiod vs Low/moderate cost preperiod, Always had cost vs Low/moderate preperiod, Never had cost vs Low/moderate cost preperiod, High cost preperiod vs Low/moderate cost pos period, Never had cost vs Low/moderate cost postperiod, Always had cost vs High cost preperiod, Never had cost vs High cost preperiod, and Never had cost vs Always had cost. low levels of cost sharing prior to the ACA. This observation is critically important to consider, particularly as policymakers contemplate further loosening the restrictions on cost sharing. Failing to recognize that cost sharing was already low could cause us to falsely conclude that the elimination of cost sharing was ineffective, which could lead to increases in OOPCs beyond pre-ACA levels.
OOPCs for POV and LARC insertion fell promptly after the implementation dates for mandated coverage of preventive services. Our study is consistent with previous work demonstrating a particularly large decline in women's OOPCs for LARC insertion. 10, 18 The 27,829 women who had LARC placements in 2015 paid about $800,000 less than they would have paid in 2008 using the average 2008 pricing.
In contrast to some previously published studies on the ACA, we identified a modest increase in LARC insertions associated with the elimination of OOPCs. 11, 12, 15 In part, our conflicting findings may reflect the fact that our analysis was conducted later, thereby allowing time for consumers to become aware of new benefits required by the ACA.
Second, most early studies were conducted among women with low OOPCs, even before the ACA, and this population may not be as responsive. Furthermore, these studies did not account for variation in baseline costs or timing. At least for LARC insertion, our finding that women who benefited most from the elimination of OOPCs had the highest rates of insertion suggests that eliminating cost sharing had a desirable impact on LARC utilization. Our findings were consistent with another study that accounted for variation in OOPCs resulting from the staggered elimination of cost sharing as plans lost grandfather status. 18 The long-term impact of eliminating cost sharing for POVs among commercially insured women is less clear. Interestingly, we found that women enrolled in plans that had high OOPCs at baseline for POVs had lower utilization rates than women with low/moderate OOPCs, even after cost sharing was eliminated. One plausible explanation for this observation is that women are generally unaware of their benefits unless they use the service at least once. Even as of 2017, many Americans are unaware that cost sharing for many preventive services was eliminated. 19 Perhaps women with high OOPCs prior to the ACA who usedand paid for-a service are more reluctant to use that service again.
In contrast to POVs, LARC insertion visits often require confirmation of insurance coverage prior to the appointment. Furthermore, because LARC devices can be left in place for many years, there would need to be a minimum of 4e6 years of follow-up to observe repeat utilization. It is also possible that differences in responsiveness to changes in OOPCs for POVs and LARC insertion are because women view the necessity of these 2 services differently.
The effect sizes identified in our analysis were small and reflect the fact that decision making around contraception use and method choice is multifactorial. Still, relatively small increases in LARC use are expected to have meaningful impacts both on unintended pregnancy rates and public spending. Trussell et al 20 estimated that if 10% of women aged 20e29 years switched from oral contraception to LARC, total costs associated with unintended pregnancy would be reduced by $288 million per year.
In our more diverse sample of contraception users, women in high-cost plans at baseline increased their annual LARC initiation rates from 3% to 4%. Because these methods have high continuation rates and can be left in place for many years, even small increases in a new device placement could translate into a clinically meaningful increase in the proportion of women using LARC over time. Studies with longer observation period would be required to more fully assess the clinical implications of our findings.
Our study has several limitations. First, by relying on administrative claims data, we cannot observe services or procedures not covered by the health plans or services obtained outside the member's health plan. This may have resulted in an underestimate of utilization rates and OOPCs, particularly in high-cost plans. It also means that we are not able to observe women in plans that went from no coverage prior to the ACA to full coverage, which would cause us to underestimate the impact of costsharing elimination. Second, because we examined a subset of health plans, our findings may not be generalizable to either commercially insured women or the general population.
Our experience with specific aspects of the ACA remains relevant as we identify policies and strategies that are aligned with our clinical and public health goals. This study of commercially insured women generates new evidence about the impact of cost sharing on women's use of preventive health services. Our findings linking the elimination of cost sharing-especially high levels of cost sharing-with higher utilization suggest insurance benefit design may be leveraged to increase the use of targeted health care services. It is important for policymakers, payers, and other stakeholders to recognize that baseline costs were already low for many commercially insured women, but women with higher costs may have had unmet demand, especially for LARC insertion. Future policies that allow high levels of cost sharing are not consistent with our clinical goals.
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